Japan’s Mitsui, U.S. Partner Sell Actimis To Boehringer
This article was originally published in PharmAsia News
Japan's Mitsui and its U.S. partner said they would sell their U.S.-based biotech Actimis Pharmaceuticals to Boehringer Ingelheim for $515 million. Actimis began in Japan, but was moved to the United States when Venture Partners joined Mitsui in investing in the biotech. The two investors decided to sell the firm when Actimis reached milestones for developing an asthma drug. The sale to Boehringer, to be completed within the next four years, is expected to help get the drug on the market. (Click here for more - a subscription may be required
You may also be interested in...
Lawyer asks US FDA to require another trial before licensing Mesoblast’s stem cell therapy for children with SR-aGVHD; Incyte’s Jakafi is only product approved for the indication.
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.
Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading.